OTC: CHGCF - Chugai Pharmaceutical Co., Ltd.

Yield per half year: -7.47%
Dividend yield: +2.96%
Sector: Healthcare

Share chart Chugai Pharmaceutical Co., Ltd.

Extended chart Simple chart
Financial Markets by TradingView

About Chugai Pharmaceutical Co., Ltd.

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.

more details
It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета jpy
Див.доход ао 3.38
Дивиденд ао 1.13
Сайт https://www.chugai-pharm.co.jp
Цена ао 49.11
Change price per day: 0% (44.23)
Change price per week: +1.24% (43.69)
Change price per month: -14.28% (51.6)
Change price per 3 month: +3.73% (42.64)
Change price per half year: -7.47% (47.8)
Change price per year: +13% (39.14)
Change price per year to date: +2.43% (43.18)
All parameters

Underestimation

Title Value Grade
P/S 7.8 1
P/BV 5.33 2
P/E 26.64 6
EV/EBITDA 18.38 6
Total: 5.38

Efficiency

Title Value Grade
ROA, % 16.84 5
ROE, % 20.02 7
Total: 6.33

Dividends

Title Value Grade
Div yield, % 2.96 7.4
DSI 0.9286 9.29
Total: 6.24

Debt

Title Value Grade
Debt/EBITDA 0.0301 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 61.96 8
Yield Ebitda, % 113.37 10
Yield EPS, % 106.17 10
Total: 9.6
More

More



Head Job title Payment Year of birth
Dr. Osamu Okuda President, CEO & Chairman 1.44M 1963 (62 years)
Toshiya Sasai Executive of Investor Relations Group & Corporate Communications Department N/A
Mr. Shinji Hidaka Executive Vice President N/A
Mr. Junichi Ebihara Executive Vice President N/A
Dr. Yoshiaki Ohashi Senior VP & Full-time Audit Supervisory Board Member N/A 1960 (65 years)
Mr. Tetsuya Yamaguchi Executive VP & Head of PHC Solution Unit N/A
Mr. Yoshiyuki Yano Executive Vice President N/A
Mr. Iwaaki Taniguchi Executive VP, Head of Finance Supervisory Division, CFO & Director 1967 (58 years)
Mr. Masayoshi Higuchi VP and Head of Quality, Regulatory Compliance Unit, Business Strategy & Compliance Dept.
Junichi Takano Head of Marketing & Sales Division

Address: Japan, Chuo, 2-1-1 Nihonbashi-Muromachi - open in Google maps, open in Yandex maps
Website: https://www.chugai-pharm.co.jp